Drug Profile
Research programme: antibody drug conjugates - ADC Therapeutics
Alternative Names: ADCT 501; Humanized anti-DLK1 antibody ADC - Chiome BioscienceLatest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator ADC Therapeutics; Cancer Research Technology
- Developer ADC Therapeutics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins
- Mechanism of Action Delta like 1 protein inhibitors; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Liver cancer
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Liver-cancer in United Kingdom
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 16 Sep 2020 Pharmacodynamics data from a preclinical study in Cancer released by Synaffix